Results 251 to 260 of about 130,782 (308)

MEK inhibitor PD0325901 upregulates CD34 expression in endothelial cells via inhibition of ERK phosphorylation. [PDF]

Regen Ther
Hosoda C, Mitani S, Sakata A, Kasuda S, Onodera Y, Takabayashi Y, Shima M, Tatsumi K.   +7 more
europepmc   +1 more source

Multiomics Research Strategies in Cancer: A Growing and Innovative Field

MedComm, Volume 7, Issue 4, April 2026.
This review highlights multiomics strategies in cancer research, focusing on integration methods from genomics to microbiomics. Using colorectal cancer as a key example, it discusses biomarker discovery, data integration via deep learning, and the roles of single‐cell and spatial omics.
Zhenhua Du, Xiaomei Liu, Zhi Lv, Bengang Wang, Yu Xia, Wala Abduljabbar Mohammed Al‐Duais, Lirong Yan, Fuqiang Zhang, Yanke Li   +8 more
wiley   +1 more source

Ocular Effects of MEK Inhibitor Therapy: Literature Review, Clinical Presentation, and Best Practices for Mitigation. [PDF]

Oncologist
Jeng-Miller KW, Miller MA, Heier JS.
europepmc   +1 more source

The Homeobox Genes: Classification, Regulation, Biological Functions, and Diseases

MedComm, Volume 7, Issue 4, April 2026.
Overview of the homeobox gene superfamily and its pathophysiological roles. The homeobox superfamily comprises several major classes, including ANTP, PRD, TALE, LIM, POU, and others. Among these, the HOX clusters (A–D) play critical roles in embryonic development specifically in conferring cellular identity, regulating morphogenesis, and guiding axial ...
Maedeh Dadzadi, Shahin Ramazi, Mona Darvazi, Sepideh Yoosefi, Melika Abbasi, Shirin Farsad   +5 more
wiley   +1 more source

Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1. [PDF]

Sci Adv
Sarin KY, Bradshaw M, O'Mara C, Shahryari J, Kincaid J, Kempers S, Tu JH, Dhawan S, DuBois J, Wilson D, Horwath P, de Souza MP, Powala C, Kochendoerfer GG, Plotkin SR, Webster GF, Le LQ.   +16 more
europepmc   +1 more source

Metabolic Alterations in Macrophage Subtypes Propel Immune and Stromal Remodeling in Neurofibroma's Malignant Progression

MedComm, Volume 7, Issue 4, April 2026.
Illustration of the microenvironment factors driving malignant progression in MPNSTs. ABSTRACT Neurofibromatosis type 1 (NF1) is characterized by the development of benign plexiform neurofibromas (PNFs). In 10%–15% of patients, these tumors undergo malignant transformation into aggressive malignant peripheral nerve sheath tumors (MPNSTs).
Ling‐Ling Ge, Yue‐Hua Li, Xuan Yu, Ming‐Yan Xing, Yi‐Hui Gu, Wei Wang, Jing‐Xuan Huang, Jun Liu, Hai‐Bing Zhang, Cheng‐Jiang Wei, Zhi‐Chao Wang, Qing‐Feng Li   +11 more
wiley   +1 more source

Dual Targeting of DNA and EGFR by ZYH005 Induces DNA Damage and Mitotic Catastrophe in Glioblastoma

MedComm, Volume 7, Issue 4, April 2026.
ZYH005 exerts potent anti‐glioblastoma activity through a dual mechanism: intercalation‐mediated DNA damage and targeted inhibition of EGFR, leading to cell cycle arrest and mitotic catastrophe. ABSTRACT Glioblastoma multiforme (GBM) is an aggressive, therapy‐resistant brain tumor with limited treatment options.
Jianzheng Huang, Zijun Zhang, Yang Xiao, Ziming Zhao, Zengwei Luo, Junjun Liu, Suitian Lai, Chao Song, Shouchang Feng, Suojun Zhang, Xingjiang Yu, Qingyi Tong, Yonghui Zhang   +12 more
wiley   +1 more source

AI‐assisted design of a VEGFR2 agonistic peptide that promotes angiogenesis and wound repair

Protein Science, Volume 35, Issue 4, April 2026.
Abstract Vascular endothelial growth factor (VEGF) serves as a principal regulator of neovascularization and is essential for vascular regeneration. In this study, we identified and evaluated VEGF Mimetic Peptide3 (VMP3), a novel synthetic peptide developed as a potential VEGFR‐2/VEGF‐A modulator.
Farzana Yasmeen, Rajath Ramachandran, Rameez Hassan Pirzada, Bogeum Choi, Hana Seo, Wook Kim, Moon Suk Kim, Sangdun Choi   +7 more
wiley   +1 more source